A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-08-27
Adverse events
Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-10-21 (study day 43); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 48); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-03 (study day 177); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-30 (study day 296); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-09-07 (study day 365); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-15 (study day 373); relationship: not assessed
Data queries
No data queries.